



Guidance on conducting vaccine effectiveness evaluations in the setting of new SARS-CoV-2 variants

INTERIM GUIDANCE

22 JULY 2021



World Health
Organization

Addendum to Evaluation of COVID-19 vaccine effectiveness: Interim guidance



Guidance on conducting vaccine effectiveness evaluations in the setting of new SARS-CoV-2 variants

INTERIM GUIDANCE

22 JULY 2021



Addendum to Evaluation of COVID-19 vaccine effectiveness: Interim guidance

WHO continues to monitor the situation closely for any changes that may affect this interim guidance. Should any factors change, WHO will issue a further update. Otherwise, this interim guidance document will expire 2 years after the date of publication.

© World Health Organization 2021. Some rights reserved. This work is available under the CC BY-NC-SA 3.0 IGO licence.

WHO/2019-nCoV/vaccine_effectiveness/variants/2021.1

Design and layout by L'IV Com Sàrl, Switzerland

Contents

Acknowledgements	iv
Abbreviations	v
1. Introduction	1
2. Surveillance for new variants	2
3. Early triggers of reduced vaccine effectiveness against new variants	3
3.1 Vaccine breakthrough cases and new variants	3
3.2 Changing epidemiology of COVID-19 as possible indication of reduced vaccine effectiveness against new variants	4
3.3 Screening method assessment using breakthrough cases to assess if vaccine effectiveness might be lower than expected in the setting of new variants	4
4. Case-only approaches to assessing vaccine effectiveness from new variants	9
4.1 Comparison of variant prevalence in vaccinated and unvaccinated cases	9
4.2 Sieve analysis	10
5. Full vaccine effectiveness evaluations for new variants	12
5.1 Evaluation of COVID-19 VE when new variant is co-circulating	12
A. When the majority of cases have genomic characterization	12
B. When a majority of cases do not have genomic characterization	13
5.2 Evaluation of COVID-19 VE when new variant is the predominant circulating strain	14
6. Analytic considerations for genomic sequencing when estimating vaccine effectiveness for new variants	15
7. Bias in vaccine effectiveness studies of new variants	16
8. Conclusion	17
References	18

Acknowledgements

This addendum was written by the following people, listed alphabetically:

Natasha Crowcroft (Department of Immunization, Vaccines, and Biologicals, WHO)

Daniel Feikin (Department of Immunization, Vaccines, and Biologicals, WHO)

Brendan Flannery (US CDC)

Rebecca Kahn (Harvard University)

Esther Kissling (Epiconcept)

Maria Knoll (Johns Hopkins Bloomberg School of Public Health)

Marc Lipsitch (Harvard University)

Olivier Le Polain de Waroux (Health Emergencies Programme, WHO)

Walt Orenstein (Emory University)

Minal Patel (Department of Immunization, Vaccines, and Biologicals, WHO)

Morgane Rolland (Walter Reed Army Institute of Research)

Marta Valenciano (Epiconcept)

Jennifer Verani (US CDC)

We thank the following people at WHO for review and comment of an earlier draft: Brett Archer, Boris Pavlin, Lorenzo Subissi, Jillian Sacks and Mick Mulders.

Abbreviations

AEFI	adverse events following immunization
aOR	adjusted odds ratio
ARDS	acute respiratory distress syndrome
aRR	adjusted relative risk
ARU	attack rate among the unvaccinated
ARV	attack rate among the vaccinated
CaCo	case-control study
CEM	cohort event monitoring
CEPI	Coalition for Epidemic Preparedness and Innovations
CI	confidence interval
CLIA	chemiluminescence immunoassays
COPD	chronic obstructive pulmonary disease
COVID-19	coronavirus disease 2019
DBP	diastolic blood pressure
ECMO	extracorporeal membrane oxygenation
ELISA	enzyme-linked immunosorbent assays
ERC	ethical review committee
EUA	Emergency Use Authorization
EUL	Emergency Use Listing
Hib	<i>Haemophilus influenzae</i> type b
HMO	health maintenance organization
ICU	intensive care unit
ILI	influenza-like illness
IVIR-AC	Immunization and Vaccine-related Implementation Research Advisory Committee (WHO)
LFI	lateral flow immunoassays
L/MICs	low- and middle-income countries
LRT	lower respiratory tract
NPI	non-pharmaceutical interventions
RDD	regression discontinuity design
rRT-PCR	real-time reverse-transcription polymerase chain reaction
RSV	respiratory syncytial virus
SAGE	Strategic Advisory Group of Experts on Immunization (WHO)
SARI	severe acute respiratory infection
SBP	systolic blood pressure
SES	socioeconomic status
STROBE	Strengthening the Reporting of Observational Studies in Epidemiology
TND	test-negative design case-control
URT	upper respiratory tract
US CDC	United States Centers for Disease Control and Prevention
VAED	vaccine-associated enhanced disease
VE	vaccine effectiveness
WHO	World Health Organization

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_23692

